Home › Funds › WAYCROSS PARTNERS, LLC › BSX

WAYCROSS PARTNERS, LLC position in BSX

BOSTON SCIENTIFIC CORP · Health Care

WAYCROSS PARTNERS, LLC reported holding 308,313 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$13.5M, representing 1.05% of its reported portfolio and ranking #29 among its reported holdings. WAYCROSS PARTNERS, LLC has disclosed BSX holdings in 5 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)308.31K sh
Reported value held$13.46M
Portfolio Weight1.05%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How WAYCROSS PARTNERS, LLC's BSX position evolved

WAYCROSS PARTNERS, LLC first disclosed a stake in BSX in Q3 2023 at 19,900 shares (US$1.1M). The position peaked in Q1 2026 at 267,646 shares, worth US$16.8M. Across 5 filings, WAYCROSS PARTNERS, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 308,313 shares valued at US$13.5M — an increase of 37,083 shares quarter over quarter.. Notable position changes include a 971% increase in Q1 2026 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 19.90K $1.05M New
Q4 2025 25.00K $2.38M New
Q1 2026 267.65K $16.79M Add
Q2 2026 271.23K $11.58M Add
Q3 2026 308.31K $13.46M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 18 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), D. E. Shaw & Co (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has WAYCROSS PARTNERS, LLC held BSX?

WAYCROSS PARTNERS, LLC has disclosed BSX holdings in 5 of the last 13 reported quarters, going back to Q3 2023.

What is WAYCROSS PARTNERS, LLC's current position in BSX?

As of Q3 2026, WAYCROSS PARTNERS, LLC holds 308.31K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $13.46M, representing 1.05% of its reported portfolio and ranking #29.

Has WAYCROSS PARTNERS, LLC been buying or selling BSX?

In the latest 13F filing (Q3 2026), WAYCROSS PARTNERS, LLC increased its position in BSX. The position peaked in Q1 2026 at 267.65K shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, D. E. Shaw & Co, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.